<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37170311</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Recurrent embolic strokes due to antiphospholipid syndrome and non-bacterial thrombotic endocarditis in a patient with basal cell carcinoma.</ArticleTitle><Pagination><StartPage>177</StartPage><MedlinePgn>177</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">177</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-023-02266-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Non-Bacterial Thrombotic Endocarditis (NBTE) is a common form of aseptic thrombotic endocarditis that primarily affects mitral valves and less frequently aortic valves. NBTE is caused by systemic inflammatory reactions. This condition induces valve thickening or attached sterile mobile vegetation. NBTE is mostly asymptomatic; however, major clinical manifestations result from systemic emboli rather than valve dysfunction. When significant damage occurs, valvular insufficiency or stenosis can appear and promote heart failure occasionally requiring valve replacement surgery. NBTE is associated with hypercoagulable states, systemic lupus erythematous (SLE), antiphospholipid syndrome, or malignancies.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We report successful biological aortic valve replacement surgery including cardiopulmonary bypass for a 78-year-old man with NBTE and voluminous vegetation on the aortic valve inducing moderate aortic insufficiency and acute heart failure. The histopathological analysis of the valve sample showed myxoid degeneration, fibrous remodeling, and partial necrosis without any bacteria, thus indicating marantic endocarditis. Initially, the patient presented to the emergency department with an acute stroke. He was already using Apixaban treatment for a history of atrial fibrillation and cardioembolic stroke. Because of the recurrence of stroke and appearance of aortic vegetation, the investigations were extended. The antiphospholipid antibodies were positive without any indication of bacterial endocarditis. The malignancy screening was positive for basal cell carcinoma (BCC). The surgery and postoperative course were uneventful, and the patient was discharged with vitamin K antagonists (VKA). To our knowledge, NBTE with such a volume is rare and its apparent association with BCC has not been previously reported.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Outside of SLE and antiphospholipid syndrome, NBTE is a rare and underdiagnosed disease associated with thromboembolic events. Adequate anticoagulation is a cornerstone of its treatment. Anticoagulation management during perioperative care and valve surgery deserves specific attention and helps to protect the patient from embolic complications. In the case of stroke and thromboembolic events of unclear cause or suspected NBTE, echocardiography and thrombophilia assessments including an immunological workup are recommended.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Svantner</LastName><ForeName>Julianna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Hospital of Valais, Sion, Switzerland. Juliana.Svantnerova@chuv.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Juliana.Svantnerova@chuv.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavanchy</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labouch&#xe8;re</LastName><ForeName>Ania</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Hospital of Valais, Sion, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Plastic and Hand Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059905" MajorTopicYN="Y">Endocarditis, Non-Infective</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000083262" MajorTopicYN="Y">Embolic Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004617" MajorTopicYN="Y">Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004696" MajorTopicYN="Y">Endocarditis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="Y">Thromboembolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002280" MajorTopicYN="Y">Carcinoma, Basal Cell</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Heart valve disease</Keyword><Keyword MajorTopicYN="N">Non-bacterial thrombotic endocarditis</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword><Keyword MajorTopicYN="N">Valve replacement surgery</Keyword></KeywordList><CoiStatement>Not applicable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>23</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37170311</ArticleId><ArticleId IdType="pmc">PMC10176810</ArticleId><ArticleId IdType="doi">10.1186/s13019-023-02266-6</ArticleId><ArticleId IdType="pii">10.1186/s13019-023-02266-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>el-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist. 2007;12:518&#x2013;23. doi: 10.1634/theoncologist.12-5-518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.12-5-518</ArticleId><ArticleId IdType="pubmed">17522239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim AM, Siddique MS. Libman Sacks Endocarditis. StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing; 2022 Jan.</Citation><ArticleIdList><ArticleId IdType="pubmed">30422459</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause I, Lev S, Fraser A, et al. Close Association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490&#x2013;3. doi: 10.1136/ard.2004.032813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.032813</ArticleId><ArticleId IdType="pmc">PMC1755247</ArticleId><ArticleId IdType="pubmed">15778242</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010&#x2013;21. doi: 10.1056/NEJMra1705454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705454</ArticleId><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bot A, J&#xe9;go P, Donal E, Fl&#xe9;cher E, Revest M, Tattevin P. Les endocardites non infectieuses. La Revue de M&#xe9;decine Interne. 2018;39(10):782&#x2013;91. doi: 10.1016/j.revmed.2018.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.revmed.2018.03.020</ArticleId><ArticleId IdType="pubmed">29903680</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmon-Levin N, Damoiseaux J, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014 Jan;73(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019 Oct;78(10):1296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar B, Almeida FM, Rebocho L, Moniz JC, Azevedo F. Cerebral embolism from Libman-Sacks endocarditis. BMJ Case Rep. 2011;2011:bcr0420114071. doi: 10.1136/bcr.04.2011.4071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr.04.2011.4071</ArticleId><ArticleId IdType="pmc">PMC3132627</ArticleId><ArticleId IdType="pubmed">22693297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo BW, Lee SW, Song JJ, Park YB, Jung SM. Clinical characteristics and long-term outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. Lupus. 2020;29(9):1115&#x2013;20. doi: 10.1177/0961203320930097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320930097</ArticleId><ArticleId IdType="pubmed">32536317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuipers RS, Berghuis MAT, Ogilvie AC, van Wissen SA, Riezebos RK. Non-bacterial thrombotic endocarditis manifested by ventricular fibrillation in a patient with low grade ovarian carcinoma: case report and literature review. Eur Heart J Case Rep. 2021;5(4):ytab120. doi: 10.1093/ehjcr/ytab120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytab120</ArticleId><ArticleId IdType="pmc">PMC8183660</ArticleId><ArticleId IdType="pubmed">34109290</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum. 1987;17:126&#x2013;41. doi: 10.1016/0049-0172(87)90035-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(87)90035-7</ArticleId><ArticleId IdType="pubmed">3334284</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J. 1985;110(6):1257&#x2013;65. doi: 10.1016/0002-8703(85)90023-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-8703(85)90023-7</ArticleId><ArticleId IdType="pubmed">3907317</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldan CA, Sibbitt WL, Jr, Qualls CR, Jung RE, Greene ER, Gasparovic CM, et al. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013;6(9):973&#x2013;83. doi: 10.1016/j.jcmg.2013.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2013.04.012</ArticleId><ArticleId IdType="pmc">PMC3941465</ArticleId><ArticleId IdType="pubmed">24029368</ArticleId></ArticleIdList></Reference><Reference><Citation>Djokovic A, Stojanovich L, Stanisavljevic N et al. l. Relationship between cerebrovascular and valvular manifestations in a Serbian cohort of patients with antiphospholipid syndrome.Clin and Exp Rheumatol. 2018 Sep-Oct;36(5):850&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">29846156</ArticleId></ArticleIdList></Reference><Reference><Citation>Djokovic A, Stojanovich L, Stanisavljevic et al. l. Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies&#x2019; types and titers-cross-sectional study of Serbian cohort. Clin Rheumatol. 2022 May;41(5):1447&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pubmed">35018582</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese KMJ, Ortel TL, Pengo V, de Laat B. Subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(4):809&#x2013;13. doi: 10.1111/jth.13976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13976</ArticleId><ArticleId IdType="pubmed">29532986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripodi A, Cohen H, et al. Guidance from Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on thrombosis and haemostasis. J Thromb Haemost. 2020 Jul;18(7):1569&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619349</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ho Y, Ahmad Zaidi NA, Salleh A, Abdul Kareem BA. Aortic valve surgery for aortic regurgitation caused by Libman-Sacks endocarditis in a patient with primary antiphospholipid syndrome: a case report. J Cardiothorac Surg. 2021;16(1):92. doi: 10.1186/s13019-021-01458-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-021-01458-2</ArticleId><ArticleId IdType="pmc">PMC8052785</ArticleId><ArticleId IdType="pubmed">33865405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med. 1989;86(4):407&#x2013;12. doi: 10.1016/0002-9343(89)90337-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(89)90337-9</ArticleId><ArticleId IdType="pubmed">2929627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J Autoimmun. 2000;15(2):123&#x2013;5. doi: 10.1006/jaut.2000.0405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.2000.0405</ArticleId><ArticleId IdType="pubmed">10968897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs MR, Lazo-Langner A, Louzada ML, Kovacs MJ. Thrombophilia testing in patients receiving rivaroxaban or apixaban for the treatment of venous thromboembolism. Thromb Res. 2020;195:231&#x2013;2. doi: 10.1016/j.thromres.2020.07.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.07.052</ArticleId><ArticleId IdType="pubmed">32799129</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassalo J, Spector N, de Meis E, Rabello LS, Rosolem MM, do Brasil PE, et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. J Crit Care. 2014;29(4):533&#x2013;8. doi: 10.1016/j.jcrc.2014.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2014.02.005</ArticleId><ArticleId IdType="pubmed">24629573</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology. 2003;207(1):5&#x2013;11. doi: 10.1078/0171-2985-00213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1078/0171-2985-00213</ArticleId><ArticleId IdType="pubmed">12638896</ArticleId></ArticleIdList></Reference><Reference><Citation>Funauchi M, Yamagata T, Sugiyama M, Ikoma SY, Sakaguchi M, Kinoshita K, et al. A case of antiphospholipid antibody syndrome that manifested in the course of basal cell carcinoma. Mod Rheumatol. 2007;17(2):153&#x2013;5. doi: 10.3109/s10165-006-0550-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/s10165-006-0550-y</ArticleId><ArticleId IdType="pubmed">17437172</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, ESC Scientific Document Group et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J. 2015;36:3075&#x2013;128. doi: 10.1093/eurheartj/ehv319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv319</ArticleId><ArticleId IdType="pubmed">26320109</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127(2):414&#x2013;20. doi: 10.1016/j.jtcvs.2003.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2003.07.016</ArticleId><ArticleId IdType="pubmed">14762349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chighizola CB, Andreoli L, Gerosa M, Tincani A, Ruffatti A, Meroni PL. The treatment of anti-phospholipid syndrome: a comprehensive clinical approach. J Autoimmun. 2018;90:1&#x2013;27. doi: 10.1016/j.jaut.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.02.003</ArticleId><ArticleId IdType="pubmed">29449131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen H, Efthymiou M, Devreese KMJ. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2021;19(4):892&#x2013;908. doi: 10.1111/jth.15217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15217</ArticleId><ArticleId IdType="pubmed">33325604</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365&#x2013;71. doi: 10.1182/blood-2018-04-848333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-04-848333</ArticleId><ArticleId IdType="pubmed">30002145</ArticleId></ArticleIdList></Reference><Reference><Citation>Laureano M, Crowther MA. Higher-risk APS: do we dare to DOAC? Blood. 2018;132(13):1357&#x2013;58. doi: 10.1182/blood-2018-08-867036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-08-867036</ArticleId><ArticleId IdType="pubmed">30262580</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krilis S, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12(7):518&#x2013;23. doi: 10.1191/0961203303lu391oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu391oa</ArticleId><ArticleId IdType="pubmed">12892391</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>